Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial"

J Psychiatr Res. 2012 May;46(5):692-3; author reply 694-5. doi: 10.1016/j.jpsychires.2012.02.002.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antidepressive Agents / therapeutic use*
  • Aza Compounds / therapeutic use*
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Female
  • Humans
  • Male

Substances

  • Antidepressive Agents
  • Aza Compounds
  • Bridged Bicyclo Compounds, Heterocyclic